Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thiothixene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | HRH1 | P35367 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiothixene SCHEMBL782605 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL718331 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL29391417 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL3715363 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL29373233 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL561321 | 0.99 | MEN1 (1.00) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL40977 | 0.98 | MEN1 (0.98) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL30903897 | 0.98 | MEN1 (0.98) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL721093 | 0.97 | CYP3A4 (0.94) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL8022212 | 0.95 | CYP3A4 (0.91) | CYP3A4LMNADRD3CYP2D6HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13948 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260092932-A1 | METHODS AND COMPOSITIONS FOR THE DETECTION, DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER | THE JOHNSON CENTER FOR CHILD HEALTH AND DEV (US) | 2026-04-02 | — | — | US | claimed |
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | HADASIT MED RES SERVICE (IL) | 2026-03-26 | — | — | US | claimed |
| US-20260034065-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2026-02-05 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | TUFTS MEDICAL CENTER, INC. (US) | 2026-01-20 | — | — | US | claimed |
| EP-4654963-A1 | TREATMENT OF MENTAL ILLNESS VIA ADMINISTRATION OF BUNTANETAP AND ANALOGUES THEREOF | Annovis Bio, Inc. (US) | 2025-12-03 | — | — | EP | claimed |
| US-5474783-A | In the form of sheet; used for applying to the dermis | NOVEN PHARMACEUTICALS, INC. (US) | 1995-12-12 | — | — | US | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
| WO-1995018603-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | claimed |
| EP-0591432-A4 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION. | NOVEN PHARMA (US) | 1995-05-17 | — | — | EP | claimed |
| CN-1088778-A | Based on the drug delivery system of solubility parameters and the method for change medicine saturated concentration | NOVEN PHARMA (US) | 1994-07-06 | — | — | CN | claimed |
| EP-0591432-A1 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION | NOVEN PHARMACEUTICALS, INC. (US) | 1994-04-13 | — | — | EP | claimed |
| WO-1993000058-A1 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION | NOVEN PHARMACEUTICALS, INC. (US) | 1993-01-07 | — | — | WO | claimed |
| US-4536403-A | WITH CARISOPRODOL | ROOKS J F GIRARD | 1985-08-20 | — | — | US | claimed |
| EP-0089948-B1 | PHARMACEUTICAL COMPOSITIONS | COPPEN, Alec James (GB) | 1985-08-14 | — | — | EP | claimed |